Caregiver Burden in Caregivers of Patients With Multiple Sclerosis

NCT07549048 · tracked via the Priya Life Science Turkey tracker

Sponsor

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Phase

Observational

Started

2026-04-20

Last updated

2026-04-23

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

Individuals aged 18-80 years who have been clinically diagnosed with multiple sclerosis and their caregivers will be included in the study.

Demographic data of the patients, including age, height, weight, and comorbidities, will be recorded. Disease-specific characteristics such as disease duration, presence of incontinence, ambulation status, and presence and severity of pain will be assessed. Functional status of the patients will be evaluated using the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Impact Scale (MSIS). Symptoms related to depression and anxiety in patients will be assessed using the Hospital Anxiety and Depression Scale (HADS).

Subsequently, caregivers of the patients will be evaluated. The severity of insomnia will be assessed using the Insomnia Severity Index (ISI). Symptoms related to anxiety and depression will be evaluated using the Hospital Anxiety and Depression Scale (HADS). Caregiver burden will be assessed using the Zarit Caregiver Burden Scale.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Age 18-80 years * Clinically diagnosed with multiple sclerosis by a neurologist * Being followed in the physical therapy and rehabilitation clinics during the study period * Having a primary or regular caregiver (family member) * Both patient and caregiver able to read and understand Turkish and complete questionnaires * Willing to participate and provide written informed consent Exclusion Criteria: * Severe cognitive impairment or communication problems preventing questionnaire completion * Acute relapse or hospitalization due to exacerbation within the last month * Severe comorbid neurological, psychiatric, or systemic disease affecting assessments * Caregiver \<18 years old or not providing regular care * Paid professional caregiver * Caregiver with severe psychiatric, neurological, or primary sleep disorder * Refusal to participate

Primary outcome measure(s)

Zarit Caregiver Burden Scale (Zarit Burden Interview, ZBI) — Baseline
Caregiver burden will be assessed using the Zarit Caregiver Burden Scale. Higher scores indicate greater caregiver burden.

Trial sites (1)

Facility	City	Region	Status
Istanbul Physical Medicine and Rehabilitation Trainig and Research Hospital	Istanbul	Bahcelievler	Recruiting

More Istanbul Physical Medicine Rehabilitation Training and Research Hospital trials in Turkey

RELATIONSHIP BETWEEN ULTRASONOGRAPHIC QUADRICEPS MUSCLE THICKNESS AND SARCOPENIA MARKERS (HANDGRIP STRENGTH, SARC-F) AND KINESIOPHOBIA IN STROKE PATIENTS Recruiting

Pain and Fascia Thickness After Steroid Injection in Plantar Fasciitis Starting soon

Night Pain Module for Rotator Cuff-Related Shoulder Pain Starting soon

FREQUENCY-DEPENDENT SOLEUS REFLEX MODULATION DURING WHOLE-BODY VIBRATION Enrolling by invitation

Turkish Validity and Reliability of the Expanded Rehabilitation Complexity Scale Recruiting

Other trials for the same condition

Effects of Balance Exercises Performed With Different Visual Stimuli Starting soon

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) Active, not recruiting

Nutritional Status and Muscle Function in Ambulatory Multiple Sclerosis Patients With Dysphagia Enrolling by invitation

Effect of Multimodal Exercise Training in Patients With Multiple Sclerosis Recruiting

Effects of Reiki and Self-Acupressure Applications Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07549048 on ClinicalTrials.gov ↗ ← All trials in Turkey